author-photo

Amy H. Comander

Harvard University

11

Papers

208

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Development and Refinement of a Telehealth Intervention for Symptom Management, Distress, and Adherence to Adjuvant Endocrine Therapy after Breast Cancer.

2020 Journal of Clinical Psychology in Medical Settings
Show All
- Source
- Cite
- Save
Citations (3)
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer

2018 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (6)
Reflections on the Boston Marathon from a Breast Cancer Oncologist (or, Why I Just Don't Quit)

2018 Oncologist
- Amy H. Comander
Show All
- Source
- Cite
- Save
Citations (0)
Determination of factors predicting for estrogen receptor positive (ER+) breast cancers in BRCA1 mutation carriers

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.

2014 Oncologist
Show All
- Source
- Cite
- Save
Citations (50)
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers

2011 Cancer
Show All
- Source
- Cite
- Save
Citations (58)
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

2010 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (78)